Statin use and cognitive function in middle-aged adults with type 1 diabetes

Table 5 Results of linear regression models assessing the association between duration of statin use and memory domain function in middle-aged adults with type 1 diabetes from the Pittsburgh Epidemiology of Diabetes Complications Study

	Variables in Model	Memory domain standardized β, P value
Model 1	Never used statins	Referent group
	1-6 yr statins	-0.284, P = 0.003
	7-12 yr statins	-0.232, P = 0.01
Model 2	Never used statins	Referent group
	1-6 yr statins	-0.267, P = 0.006
	7-12 yr statins	-0.209, P = 0.031
	Average LDLc	-0.084, P = 0.34
Model 3	Never used statins	Referent group
	1-6 yr statins	-0.267, P = 0.006
	7-12 yr statins	-0.213, P = 0.032
	CAD	0.02, P = 0.86
Model 4	Never used statins	Referent group
	1-6 yr statins	-0.284, P = 0.003
	7-12 yr statins	-0.231, P = 0.014
	Apo E4 allele	-0.01, P = 0.92
Model 5	Never used statins	Referent group
	1-6 yr statins	-0.267, P = 0.007
	7-12 yr statins	-0.213, P = 0.034
	Average LDLc	-0.084, P = 0.35
	CAD	0.02, P = 0.86
	Apo E4 allele	-0.001, P = 0.99

Statin use groups: Never used n = 51; 1-6 years n = 25; 7-12 years n = 32. Outcome: Standardized score of seven tasks assessing memory domain (z-score, in SD units). Model 1: Statin use groups, controlling for age and education; Model 2: Model 1, further controlling for average long-term LDLc (1986-88 through 2010-2013); Model 3: Model 1, further controlling for prevalent coronary artery disease (CAD) as of 2004-2006; Model 4: Model 1, further controlling for Apo E4 allele status (24, 34, or 44); Model 5: Model 1, further controlling for LDLc, CAD, and Apo E4 allele. LDLc: Low density lipoprotein cholesterol.